What does the licensing of teplizumab mean for diabetes care?

Lauren M Quinn¹, Rabbi Swaby², Danijela Tatovic², Parth Narendran^{1

3}, Rachel E J Besser^{2

4}, Colin M Dayan^{2

5}

Affiliations

¹ Institute of Immunology and Immunotherapy, University of Birmingham, Birmingham, UK.
² Wellcome Centre for Human Genetics, University of Oxford, Oxford, UK.
³ Department of Diabetes, University Hospitals of Birmingham, Birmingham, UK.
⁴ Department of Paediatrics, National Institute for Health Research Oxford Biomedical Research Centre, John Radcliffe Hospital, Oxford, UK.
⁵ Diabetes Research Group, Cardiff University School of Medicine, Cardiff, UK.

Lauren M Quinn et al. Diabetes Obes Metab. 2023 Aug.

. 2023 Aug;25(8):2051-2057.

doi: 10.1111/dom.15071. Epub 2023 Apr 24.

Lauren M Quinn¹, Rabbi Swaby², Danijela Tatovic², Parth Narendran^{1

3}, Rachel E J Besser^{2

4}, Colin M Dayan^{2

5}

¹ Institute of Immunology and Immunotherapy, University of Birmingham, Birmingham, UK.
² Wellcome Centre for Human Genetics, University of Oxford, Oxford, UK.
³ Department of Diabetes, University Hospitals of Birmingham, Birmingham, UK.
⁴ Department of Paediatrics, National Institute for Health Research Oxford Biomedical Research Centre, John Radcliffe Hospital, Oxford, UK.
⁵ Diabetes Research Group, Cardiff University School of Medicine, Cardiff, UK.

No abstract available

Keywords: autoantibodies; screening; teplizumab; type 1 diabetes.

References

1. FDA. FDA Approves First Drug That Can Delay Onset of Type 1 Diabetes. 2022. [January 10, 2023]. Available from: https://www.fda.gov/news-events/press-announcements/fda-approves-first-d....
1. Dayan CM, Besser REJ, Oram RA, et al. Preventing type 1 diabetes in childhood. Science. 2021;373(6554):506-510.
1. Anderson RL, DiMeglio LA, Mander AP, et al. Innovative designs and logistical considerations for expedited clinical development of combination disease-modifying treatments for type 1 diabetes. Diabetes Care. 2022;45(10):2189-2201.
1. DiMeglio LA, Evans-Molina C, Oram RA. Type 1 diabetes. Lancet. 2018;391(10138):2449-2462.
1. Oram RA, Sims EK, Evans-Molina C. Beta cells in type 1 diabetes: mass and function; sleeping or dead? Diabetologia. 2019;62(4):567-577.